GCT3013-01: A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma (GCT3013-01)

Principal investigator: Sirpa Leppä
Trial site: HUS Comprehensive Cancer Center